Gog0261 A Randomized Phase III Trial Of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel In Chemotherapy - Naïve Patients With Newly Diagnosed Stage I-Iv Persistent Or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) Of The Uterus
Posted Date: Jun 10, 2019
- Investigator: Thomas Herzog
- Specialties: Cancer, Oncology, Ovarian Cancer
- Type of Study: Drug
To determine if treatment with combination paclitaxel and carboplatin (TC) chemotherapy does not result in an inferior death rate when compared to ifosfamide, mesna, and paclitaxel chemotherapy.
Criteria:
To Be Eligible: Must Be 18 Years Of Age Or Older, Must Have Newly Diagnosed Uterine Carcinosarcoma, Must Be Free Of Active Infection Requiring Antibiotics, No Prior Cytotoxic Chemotherapy.
Keywords:
Ovarian Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com